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Background: Environmental exposures to phthalates, particularly high-molecular-weight (HMW) 
phthalates, are suspected to contribute to allergy.
oBjective: We assessed whether phthalate metabolites are associated with allergic symptoms and 
sensitization in a large nationally representative sample.
Methods: We used data on urinary phthalate metabolites and allergic symptoms (hay fever, rhi-
nitis, allergy, wheeze, asthma) and sensitization from participants ≥ 6 years of age in the National 
Health and Nutrition Examination Survey (NHANES) 2005–2006. Allergen sensitization was 
defined as a positive response to at least one of 19 specific IgE antigens (≥ 0.35 kU/L). Odds ratios 
(ORs) per one log10 unit change in phthalate concentration were estimated using logistic regression 
adjusting for age, race, body mass index, gender, creatinine, and cotinine. Separate analyses were 
conducted for children (6–17 years of age) and adults.
results: The HMW phthalate metabolite mono benzyl phthalate (MBzP) was the only metabo-
lite positively associated with current allergic symptoms in adults (wheeze, asthma, hay fever, and 
rhinitis). Mono-(3-carboxypropyl) phthalate and the sum of diethylhexyl phthalate metabolites 
(both representing HMW phthalate exposures) were positively associated with allergic sensitiza-
tion in adults. Conversely, in children, HMW phthalate metabolites were inversely associated with 
asthma and hay fever. Of the low-molecular-weight phthalate metabolites, mono ethyl phthalate was 
inversely associated with allergic sensitization in adults (OR = 0.79; 95% CI: 0.70, 0.90).
conclusion: In this cross-sectional analysis of a nationally representative sample, HMW phthalate 
metabolites, particularly MBzP, were positively associated with allergic symptoms and sensitization 
in adults, but there was no strong evidence for associations between phthalates and allergy in chil-
dren 6–17 years of age.
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2013. Phthalate exposure and allergy in the U.S. population: results from NHANES 2005–2006. 
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Introduction
Phthalates are common industrial chemicals 
used in cosmetics, personal care products, plas-
tics, and building materials. Exposures are fre-
quent, but the contributions of specific sources 
are poorly characterized. Phthalates represent 
a broad chemical class that includes both low-
molecular-weight (LMW) compounds such as 
diethyl phthalate (DEP) and relatively high-
molecular-weight (HMW) compounds such 
as diethylhexyl phthalate (DEHP) and butyl-
benzyl phthalate (BBzP). LMW phthalates are 
most commonly found in cosmetics and per-
sonal care products, whereas HMW phthalates 
are most associated with plastics, particularly 
polyvinyl chloride (PVC) building materials 
(Buckley et al. 2012; Carlstedt et al. 2012; 
Hauser and Calafat 2005). Results from dietary 
intervention studies suggest that food packag-
ing is the primary source of human exposure to 
DEHP, but not BBzP (Koch et al. 2013; Rudel 
et al. 2011). BBzP exposure is associated with 
PVC flooring and other building materials in 
the home (Carlstedt et al. 2012).
Phthalates and other plasticizing chemicals 
have been associated with wheeze, allergies, 
and asthma among children (Bornehag 
and Nanberg 2010; Bornehag et al. 2004; 
Choi et al. 2010; Hsu et al. 2011; Just et al. 
2012a, 2012b; Kolarik et al. 2008; Larsson 
et al. 2007) and adults (Jaakkola and Knight 
2008; Jaakkola et al. 2006). Recent studies 
have measured phthalate levels in urine or 
dust, although earlier studies suggested a role 
for phthalates due to the presence of plastic 
materials in the home (Jaakkola and Knight 
2008; Larsson et al. 2007), exposure to PVC 
plastics in an occupational setting (Jaakkola 
and Knight 2008) or use of synthetic bedding 
(Ponsonby et al. 2003). As the evidence for 
a potential role for phthalates in respiratory 
and allergic outcomes has increased, there is 
greater interest in HMW phthalates such as 
DEHP and BBzP, with evidence both from 
human and animal studies (Dearman et al. 
2009; Deutschle et al. 2008; Jaakkola and 
Knight 2008; Koike et al. 2009; Larsen et al. 
2007; Nishioka et al. 2012). These HMW 
phthalates alter immune responses in animal 
and in vitro models (Koike et al. 2009; Larsen 
et al. 2007). In addition, other studies sug-
gest that DEHP and other plasticizers may act 
as adjuvants to enhance the allergic response 
(Kimber and Dearman 2010).
Recent reports have stressed the need to 
understand the potential allergic health effects 
of phthalates (Dodson et al. 2012; Hulin et al. 
2012; Kwak et al. 2009). Although some 
evidence suggests a role of phthalates in the 
etiology of allergic sensitization and allergic 
symptoms, there is a paucity of population-
based data, particularly among adults. To 
address this, we evaluated the association 
of specific phthalate metabolites with mea-
sures of allergic symptoms and sensitization 
in a representative sample of the U.S. popu-
lation, the National Health and Nutrition 
Examination Survey (NHANES) 2005–2006.
Methods
We used publicly available data from 
NHANES 2005–2006 [Centers for Disease 
Control and Prevention (CDC 2012)] to eval-
uate the association of phthalates and allergy. 
NHANES 2005–2006 collected detailed 
data on allergic symptoms and sensitization, 
so both question naire and biochemical mea-
sures of allergy are available for all NHANES 
participants > 1 year of age (n = 8,338). At 
the time of recruitment, all study participants 
provided informed consent. All data were 
anonymized prior to becoming publicly avail-
able. Urinary phthalate concentrations were 
measured in a random sample of participants 
≥ 6 years of age (n = 2,548). Our analysis is 
limited to the 2,325 individuals who had com-
plete information on allergy, urinary phthalate 
 concentrations, and model covariates.
We assessed both self-reported current 
allergic symptoms and allergic sensitization as 
measured by specific IgE (sIgE). Information 
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on current allergic symptoms was obtained 
from self-administered questionnaires com-
pleted at the NHANES clinic visit. Subjects 
< 16 years of age were interviewed with a 
proxy respondent, usually a parent, respon-
sible for completing the interview. The ques-
tionnaire asked about six allergic conditions 
(asthma, wheeze, hay fever, allergy, itchy rash, 
and rhinitis) in the past year.
Serum samples were analyzed for allergen-
specific IgEs using the Pharmacia Diagnostics 
ImmunoCAP 1000 System (Kalamazoo, MI, 
USA). A total of 19 allergen-specific IgEs 
(Dermatophagoides farinae, Dermatophagoides 
pteronyssinus, cat, dog, cockroach, Alternaria 
alternata, peanut, egg white, cow’s milk, rag-
weed, rye grass, bermuda grass, oak, birch, 
shrimp, Aspergillus fumigatus, Russian thistle, 
mouse, and rat) were assessed. Individuals who 
tested positive (≥ 0.35 kU/L) to at least one 
allergen were considered allergen sensitized 
(sIgE positive). Information on sensitization to 
specific allergens from NHANES 2005–2006 
has been published elsewhere (Salo et al. 2011).
Fifteen phthalate metabo lites were mea-
sured in spot urine samples using high per-
formance liquid chromatography– electrospray 
ionization–tandem mass spectrometry 
(HPLC-ESI-MS/MS) at the National Center 
for Environmental Health laboratory (CDC, 
Atlanta, GA, USA) (CDC 2009). Four of these 
analytes were primary [mono-(2-ethyl)-hexyl 
phthalate (MEHP)] or secondary metabolites 
[mono-2-ethyl-5-carboxypentyl phthalate 
(MECPP), mono-(2-ethyl-5-hydroxy hexyl) 
phthalate (MEHHP), and mono(2-ethyl-
5-oxohexyl) phthalate (MEOHP)] of DEHP. 
We summed the concentrations of all four 
metabolites to create a summary DEHP vari-
able (∑DEHP) for analysis; individual DEHP 
metabolites were not analyzed because of their 
common sources and the resulting high cor-
relation among these metabolites (77–98%). 
We analyzed all chemicals that were detected in 
≥ 25% of the population; for values below the 
detection limit, we assigned a value of the limit 
of detection (LOD) divided by the square root 
of 2 (Hornung and Reed 1990).
Information on covariates was obtained 
either via questionnaire (e.g., demographic 
characteristics, smoking status) or via mea-
surement [e.g., body mass index (BMI)]. 
Urinary creatinine levels were measured using 
the Jaffe rate reaction with a CX3 analyzer 
(Beckman Instruments, Brea, CA, USA).
We used logistic regression models adjusted 
for study design using sampling weights to esti-
mate associations of urinary phthalates with 
measures of allergic sensitization and allergic 
symptoms. Urinary phthalate concentra-
tions were log10-transformed because of non-
normality of the distribution. Models were 
adjusted for age (continuous), race/ethnicity 
(non-Hispanic white, non-Hispanic black, 
Mexican American, other), gender, creatinine 
(log10 transformed, continuous), BMI (cate-
gories), and cotinine (categories). Cotinine 
was classified as < LOD (0.015 ng/mL), low 
exposure (< 10 ng/mL) and high exposure 
(≥ 10 ng/mL). For adults, BMI was calcu-
lated as body weight in kilograms divided by 
height in meters squared and categorized as 
underweight or normal (< 25), overweight 
(25 to 30), or obese (≥ 30). For children, BMI 
was classified as the age percentile underweight 
or normal (< 85th percentile), overweight 
(85–95th percentile), obese (≥ 95th percentile) 
(Krebs et al. 2007). Similar modeling strategies 
have been employed for previous analyses of 
these outcomes in the NHANES 2005–2006 
data (Salo et al. 2011). We also evaluated pov-
erty income ratio [PIR, three categories: low 
(≤ 1.3), middle (1.3–3.5), and high (> 3.5) 
income] as a potential confounder because 
previous analyses have shown an association 
between socioeconomic status and phthal-
ate concentrations in women (Kobrosly et al. 
2012) and allergic sensitization in children in 
NHANES 2005–2006 (Visness et al. 2009). 
Adjustment for PIR did not substantially alter 
our odds ratio (OR) estimates. Therefore, to 
maximize the observations included in our 
models, we did not include PIR as a covariate 
(100 missing observations). Data for children 
(6–17 years of age) and adults were analyzed 
separately because both the covariate structure 
and the outcome prevalence differed between 
adults and children. Because phthalate con-
centrations and allergic sensitization rates differ 
by race/ethnicity, we assessed potential inter-
action by race/ ethnicity in four categories by 
including three two-way inter action terms in 
our models and performed a likelihood ratio 
test (3 degrees of freedom) comparing the fit 
of models with and without the inter action 
terms to assess whether statistical inter action 
was present. In addition, we explored whether 
findings for mono benzyl phthalate (MBzP) 
and allergic symptoms were related to allergic 
sensitization by expanding our logistic regres-
sion models to four-level polytomous models 
(allergic sensitization + symptom, symptom 
without sensitization, sensitization without 
symptom, and no symptom + no sensitiza-
tion) for each of the four symptoms (asthma, 
wheeze, rhinitis, hay fever). To test whether 
the ORs differed across the four strata, we used 
a contrast statement; a p-value for difference 
was the result of this contrast test. All statistical 
modeling was done using survey procedures 
in SAS, version 9.3 (SAS Institute Inc., Cary, 
NC, USA). A p-value ≤ 0.05 was considered 
statistically significant.
Results
Rhinitis was the most common symptom 
among both children and adults (Table 1). 
Current hay fever was reported half as often in 
children (3.6%) as in adults (7.4%). Allergen 
sensitization was common, with 46% of chil-
dren and 44% of adults being sensitized to at 
least one sIgE.
Table 1. Demographic, medical, and allergic characteristics for the adults (n = 1,546) and children 6–17 
years of age (n = 779) with urinary phthalate metabolite data, NHANES 2005–2006.
Characteristic
Children Adults
n Weighted percent (SE) n Weighted percent (SE)
Age (years)a 779 11.9 (0.1) 1,546 45.6 (0.9)
Race/ethnicity
Non-Hispanic white 216 63.5 (3.8) 752 72.2 (3.1)
Non-Hispanic black 223 12.3 (2.0) 372 11.6 (2.2)
Mexican American 274 13.2 (1.7) 311 7.7 (1.0)
Other 66 10.9 (1.9) 111 8.4 (1.3)
Gender
Female 372 47.1 (2.3) 792 51.1 (1.7)
Male 407 52.9 (2.3) 754 48.9 (1.7)
Cotinine (ng/mL)
< LOD (< 0.015) 169 22.0 (3.3) 286 17.9 (2.0)
Low (≥ 0.015–10) 564 71.3 (3.4) 849 52.7 (2.0)
High (≥ 10) 46 6.7 (0.9) 411 29.5 (1.1)
BMIb
Underweight/normal 505 70.7 (2.4) 494 33.2 (1.4)
Overweight 123 16.4 (1.9) 515 32.1 (1.4)
Obese 151 12.9 (2.1) 537 34.8 (1.7)
Current allergic conditionsc
Allergy 125 18.1 (2.6) 290 22.9 (1.0)
Asthma 65 8.4 (1.2) 116 7.4 (0.8)
Hay fever 23 3.6 (0.9) 88 7.4 (0.9)
Itchy rash 43 5.2 (1.0) 118 7.8 (0.7)
Rhinitis 188 27.6 (2.7) 498 35.4 (1.2)
Wheeze 80 10.7 (1.6) 219 16.6 (1.3)
Allergic sensitization—any sIgE 406 46.1 (2.8) 717 44.0 (1.0)
aWeighted mean is reported for age. bChild BMI covariate is age percentile; adult BMI covariate is actual BMI (kg/m2). 
cSelf-reported current symptoms in past 12 months; current symptoms of asthma, hay fever, or allergy were assessed 
only among those who reported a doctor’s diagnosis.
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Both LMW and HMW phthalates 
were detected in the urine of all participants 
(Table 2). Mono ethyl phthalate (MEP) was 
the most commonly detected LMW phthal-
ate metabolite. All the HMW phthalate 
metabolites, except mono-isononyl phthalate 
(MiNP), mono-cyclohexyl phthalate (MCHP), 
and mono-n-octyl phthalate (MOP) were 
detectable in the majority of samples. The 
distributions of all LMW and HMW phthal-
ates spanned three orders of magnitude. 
Concentrations and distributions of phthal-
ates were similar for children and adults (see 
Supplemental Material, Tables S1 and S2, 
respectively).
MBzP was the metabolite most consis-
tently associated with allergic symptoms in 
adults (Table 3). It was positively associated 
with current asthma [OR = 1.46; 95% confi-
dence interval (CI): 1.01, 2.11], current 
wheeze (OR = 1.78; 95% CI: 1.22, 2.60), 
current hay fever (OR = 1.68; 95% CI: 
1.09, 2.59), and current rhinitis (OR = 1.24; 
95% CI: 1.01, 1.52). In models adjusted 
for PIR, the OR for MBzP and current 
asthma increased (1.54; 95% CI: 0.98, 2.42) 
but was no longer statistically significant; 
no other estimates changed their statistical 
signifi cance after PIR adjustment. No other 
HMW phthalate metabolite was significantly 
associated with allergic symptoms in adults. 
Current asthma in children was inversely asso-
ciated with ∑DEHP and mono(carboxy octyl) 
phthalate (MCOP), but not with MBzP or 
other HMW metabolites (Table 4). Individual 
metabolites also were inversely associated with 
current hay fever in children, specifically, the 
butyl phthalate metabolites mono-isobutyl 
phthalate (MiBP) and mono-n-butyl phthalate 
(MnBP), as well as mono-(3-carboxylpropyl) 
phthalate (MCPP), and MBzP. MEP was 
inversely associated with current hay fever in 
adults, but not children. No phthalates were 
associated with current itchy rash or cur-
rent allergy in either children or adults (data 
not shown).
Phthalate metabolites, particularly those 
from HMW chemicals, were positively 
associated with allergic sensitization in adults, 
but not in children (Table 5). Specifically, 
∑DEHP and MCPP were significantly asso-
ciated with being sIgE positive. Conversely, 
MEP was inversely associated with allergic 
sensitization in adults; other LMW phthalates 
were not. Similar findings were observed when 
Table 2. Urinary phthalate metabolite concentrations (µg/L) for NHANES 2005–2006 participants.
Metabolite LOD > LOD (%) GM (GSE) 
Percentile
5th 25th 50th 75th 95th
LMW
MiBP Mono-isobutyl phthalate 0.3 97.1 5.19 (0.30) 0.47 2.48 5.70 11.75 31.96
MnBP Mono-n-butyl phthalate 0.6 99.5 19.55 (0.81) 2.91 10.19 20.06 39.88 106.30
MEP Monoethyl phthalate 0.5 99.6 109.24 (6.33) 11.92 38.52 101.83 288.68 1457.35
MMP Mono-n-methyl phthalate 1.1 38.0 1.51 (0.07) < LOD < LOD < LOD 2.52 12.46
HMW
MBzP Monobenzyl phthalate 0.2 98.4 8.22 (0.52) 0.68 3.72 8.73 20.45 66.64
MCOP Mono(carboxyoctyl) phthalate 0.7 95.1 5.35 (0.36) 0.55 2.35 4.98 10.86 52.74
MCNP Mono(carboxynonyl) phthalate 0.6 89.9 2.71 (0.11) < LOD 1.32 2.61 5.21 17.42
MCPP Mono-(3-carboxypropyl) phthalate 0.2 96.1 2.04 (0.10) 0.22 0.98 2.02 4.21 13.04
MCHP Mono-cyclohexyl phthalate 0.6 2.2 0.44 (0.00) < LOD < LOD < LOD < LOD < LOD
MiNP Mono-isononyl phthalate 1.2 13.0 1.05 (0.02) < LOD < LOD < LOD < LOD 3.52
MOP Mono-n-octyl phthalate 1.8 1.1 1.32 (0.00) < LOD < LOD < LOD < LOD < LOD
∑DEHP ∑Diethylhexyl phtalate 85.47 (4.10) 11.36 36.23 77.28 174.02 930.24
MEHP Mono-(2-ethyl)-hexyl phthalate 1.2 66.6 3.01 (0.13) < LOD < LOD 2.40 6.26 41.37
MECPP Mono-2-ethyl-5-carboxypentyl phthalate 0.6 100.0 38.28 (1.90) 5.10 16.44 34.40 78.83 384.99
MEHHP Mono-(2-ethyl-5-hydroxyhexyl) phthalate 0.7 99.8 25.35 (1.23) 2.85 10.51 23.33 55.02 305.09
MEOHP Mono-(2-ethyl-5-oxohexyl) phthalate 0.7 98.9 16.14 (0.81) 1.85 6.63 14.99 35.30 184.95
Abbreviations: GM, geometric mean; GSE, geometric standard error of the mean. Below LOD fill values were determined as LOD divided by the square root of 2; imputed values were 
used in the calculation of GM (GSE). Restricted to participants with all covariates in logistic regression model age, race/ethnicity, gender, cotinine, BMI, creatinine.
Table 3. Associations [OR (95% CI)a] between urinary phthalate metabolite concentration and current 
allergic symptoms in adults (n = 1,596), NHANES 2005–2006.
Metabolite
Current asthma 
(n = 116)
Current wheeze 
(n = 219)
Current hay fever 
(n = 88)
Current rhinitis 
(n = 498)
LMW
MiBP 1.39 (0.77, 2.50) 0.92 (0.57, 1.48) 0.93 (0.46, 1.87) 0.99 (0.76, 1.29)
MnBP 1.75 (0.67, 4.56) 1.36 (0.74, 2.53) 1.23 (0.54, 2.79) 1.34 (0.83, 2.17)
MEP 1.12 (0.80, 1.57) 1.06 (0.81, 1.39) 0.68 (0.47, 1.00) 1.03 (0.85, 1.23)
MMP 1.29 (0.70, 2.37) 1.20 (0.80, 1.79) 0.59 (0.33, 1.05) 0.91 (0.66, 1.25)
HMW
MBzP 1.46 (1.01, 2.11) 1.78 (1.22, 2.60) 1.68 (1.09, 2.59) 1.24 (1.01, 1.52)
MCOP 0.96 (0.73, 1.25) 0.83 (0.58, 1.18) 0.64 (0.37, 1.11) 0.97 (0.76, 1.25)
MCNP 0.99 (0.65, 1.49) 1.09 (0.79, 1.52) 0.66 (0.41, 1.07) 0.93 (0.59, 1.44)
MCPP 1.40 (0.78, 2.54) 1.41 (0.85, 2.34) 0.83 (0.43, 1.60) 0.98 (0.74, 1.30)
∑DEHP 1.16 (0.82, 1.64) 1.23 (0.86, 1.77) 1.09 (0.59, 2.01) 1.09 (0.86, 1.38)
All models were adjusted for age, race, gender, BMI, creatinine, and cotinine.
aORs for 1-log10 increase in urinary phthalate concentration.
Table 4. Associations [OR (95% CI)a] between urinary phthalate metabolite concentrations and current 
allergic symptoms in children 6–17 years of age (n = 779), NHANES 2005–2006.
Metabolite
Current asthma 
(n = 65)
Current wheeze 
(n = 80)
Current hay fever 
(n = 23)
Current rhinitis 
(n = 188)
LMW
MiBP 0.92 (0.26, 3.29) 1.08 (0.49, 2.35) 0.12 (0.04, 0.39) 0.84 (0.53, 1.33)
MnBP 0.63 (0.20, 2.02) 0.45 (0.20, 0.98) 0.07 (0.03, 0.17) 0.83 (0.46, 1.52)
MEP 0.90 (0.44, 1.85) 0.99 (0.46, 2.16) 0.58 (0.16, 2.13) 0.89 (0.65, 1.23)
MMP 1.15 (0.68, 1.95) 1.10 (0.67, 1.80) 1.01 (0.31, 3.25) 1.32 (0.80, 2.17)
HMW
MBzP 1.06 (0.33, 3.45) 0.92 (0.35, 2.37) 0.42 (0.22, 0.79) 1.02 (0.62, 1.67)
MCOP 0.74 (0.36, 1.52) 1.16 (0.65, 2.07) 0.54 (0.11, 2.56) 1.40 (0.83, 2.37)
MCNP 0.50 (0.25, 0.97) 0.81 (0.31, 2.12) 0.76 (0.13, 4.58) 1.23 (0.71, 2.13)
MCPP 0.69 (0.33, 1.43) 0.87 (0.48, 1.58) 0.12 (0.02, 0.63) 1.02 (0.65, 1.58)
∑DEHP 0.26 (0.14, 0.49) 0.58 (0.24, 1.42) 0.78 (0.18, 3.48) 1.52 (0.86, 2.66)
All models were adjusted for age, race, gender, BMI, creatinine, and cotinine.
aORs for 1-log10 increase in urinary phthalate concentration.
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we analyzed allergen subgroups (e.g., indoor 
allergens; data not shown).
When we evaluated potential inter-
actions by race/ethnicity, only the inter action 
between MEP and sIgE sensitization in adults 
was statistically significant (inter action p-value 
< 0.001). As shown in Figure 1A, a log10 
increase in MEP concentration was positively 
associated with sensitization in Mexican-
American adults, but inversely associated with 
sensitization in all other adult race/ethnicity 
groups. Among children, the inter action by 
race/ethnicity was not significant and the 
pattern was less clear. The results suggested 
that in Mexican-American children, there 
was a positive association with MEP and sIgE 
(OR = 1.38; 95% CI: 0.92, 2.07; Figure 1B) 
and potentially an association with children 
of other race/ethnicity (OR = 3.72; 95% 
CI: 0.87, 15.87); however, the sample size 
was small and the CI wide, and there was 
no association among non-Hispanic whites 
and blacks.
The results from polytomous regression 
models of associations between MBzP and 
each of the four symptoms (asthma, wheeze, 
rhinitis, hay fever) in the presence or absence 
of allergic sensitization (allergic sensitization 
+ symptom, symptom without sensitization, 
sensitization without symptom, and no symp-
tom + no sensitization) suggest that adults 
with allergen sensitization were more likely to 
have wheeze (pdifference < 0.001) and asthma 
(pdifference = 0.011) associated with MBzP 
than those without sensitization or with aller-
gic sensitization alone (Table 6). For hay fever 
and rhinitis there was no statistical difference 
in the ORs for those with and without sensi-
tization. For children, although there was no 
association with MBzP with allergic sensitiza-
tion or symptoms alone, when we assessed 
the symptoms based on allergic sensitization 
status, individuals with both allergic sensitiza-
tion and symptoms had the highest odds of 
exposure. Although the individual ORs had 
95% CIs that included the null value, the 
contrast tests for differences among the ORs 
indicated significant differences for wheeze 
based on 80 cases (pdifference = 0.047) and hay 
fever based on 23 cases (pdifference = 0.011).
Discussion
Our most consistent finding was for MBzP 
and allergic symptoms in adults. MBzP was 
positively associated with current asthma, cur-
rent wheeze, current hay fever, and current 
rhinitis as well as, but nonsignificantly, with 
allergic sensitization. There was some sug-
gestion that the association between MBzP 
and allergic symptoms was driven by allergic 
sensitization, but the evidence was not strong. 
MBzP is the primary metabolite of BBzP, an 
HMW phthalate used in plastics and other 
materials in the home. In a population-based 
case–control study conducted from 1997 
to 2000, Jaakkola et al. (2006) reported that 
plastic wall materials in the home were asso-
ciated with incident asthma among 1,453 
Finnish adults. There is increasing evidence 
that MBzP may be associated with allergic 
outcomes. Prenatal urinary MBzP levels were 
associated with the development of eczema 
by 5 years of age in 407 children in a birth 
cohort study (Just et al. 2012b) and with 
increased airway inflammation as measured 
by exhaled nitric oxide (Just et al. 2012a). 
In a cross-sectional study of 101 Taiwanese 
children 3–9 years of age, BBzP concentra-
tion in house dust was associated with aller-
gic symptoms and asthma (Hsu et al. 2011). 
Although some phthalates, particularly di-
n-butyl phthalate, are included in pharma-
ceuti cals (Hernández-Díaz et al. 2009), 
BBzP is not approved for pharmaceutical use 
and, thus, MBzP in urine is unlikely to be a 
consequence of the use of allergy or asthma 
medications.
Much of the mechanistic work to date on 
phthalates and allergy has focused on DEHP 
and its ability to modulate responses to 
allergens (Jaakkola and Knight 2008; Kimber 
and Dearman 2010). In murine models and 
in human lung epithelial cells, DEHP, but not 
BBzP, has been shown to have an adjuvant 
effect on immune response to allergens (Guo 
et al. 2012; Koike et al. 2009; Larsen et al. 
2007; Nishioka et al. 2012). In a small human 
study, 16 adults with sensitivity to house dust 
mites and 16 without sensitivity were exposed 
to airborne dust containing low or high levels 
of DEHP. Those exposed to high levels had 
an attenuated immune response, whereas 
those exposed at low levels had mucosal 
inflammation and non sensitized individuals 
had no response (Deutschle et al. 2008). 
In murine models, BBzP enhanced anti-
ovalbumin responses at high doses, but not 
at the lower doses potentially more consistent 
with human exposures (Dearman et al. 2009). 
Few studies have evaluated whether BBzP, 
or its metabolite MBzP, have independent 
effects on immune responses at levels rele-
vant to human exposure. One study reported 
that topical administration of BBzP did not 
stimulate an immune response in mice (Butala 
et al. 2004). Our results for DEHP and allergic 
sensitization in adults are consistent with 
the mechanistic data; however, we have no 
information on allergen exposure.
LMW phthalates were not positively 
associated with allergic symptoms or sensiti-
zation, except for MEP and allergic sensiti-
zation among Mexican Americans. All other 
race/ ethnicity groups had inverse associations 
between sIgE and MEP. In addition, MEP 
was also inversely associated with hay fever 
and allergic sensitization in adults. In a previ-
ous NHANES sample (1999–2000), MEP 
levels among Mexican Americans were not 
different from non-Hispanic whites and were 
lower than for non-Hispanic blacks (Silva 
et al. 2004), suggesting exposure level did not 
explain the observed difference. Interestingly, 
in a study of Dominican (67%) and African-
American (33%) children 5–9 years of age, 
Just et al. (2012a) reported that children with 
higher urinary levels of MEP had higher frac-
tional exhaled nitric oxide. There was limited 
Table 5. ORs (95% CIs)a for sIgE sensitizationb with urinary phthalate 
metabolite concentration in adults and children 6–17 years of age, 
NHANES 2005–2006.
Metabolite Adults Children
LMW
MiBP 1.32 (0.99, 1.76) 0.93 (0.51, 1.70)
MnBP 1.14 (0.74, 1.74) 1.14 (0.68, 1.93)
MEP 0.79 (0.70, 0.90) 1.24 (0.80, 1.94)
MMP 0.88 (0.65, 1.20) 0.83 (0.56, 1.23)
HMW
MBzP 1.41 (0.96, 2.06) 1.18 (0.74, 1.86)
MCOP 1.21 (0.95, 1.54) 0.69 (0.40, 1.18)
MCNP 1.23 (0.86, 1.75) 0.73 (0.44, 1.23)
MCPP 1.53 (1.12, 2.10) 0.69 (0.46, 1.03)
∑DEHP 1.41 (1.12, 1.79) 1.14 (0.79, 1.65)
All models adjusted for age, race, gender, BMI, creatinine, and cotinine.
aOR for 1 log10 unit change in urinary phthalate level. bPositive for at least one of 
19 allergen-specific IgEs (≥ 0.35 kU/L).
Figure 1. MEP and allergic sensitization by race in adults (A) and children 6–17 years 
of age (B).
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evidence for differences between Dominican 
and African-American children for MEP 
exposure and allergic sensitization in children, 
but the sample sizes were small. In a Japanese 
cross-sectional study of 134 residents of 41 
dwellings conducted in 2006–2007, DEP 
was inversely associated with respiratory and 
allergic symptoms in both children and adults, 
consistent with our results (Kanazawa et al. 
2010). It is possible that both age and race/
ethnicity may influence allergic response to 
MEP, but currently the data are too limited 
to explore this extensively. MEP is the pri-
mary metabolite of DEP, a phthalate primarily 
used in fragrances (Api 2001). Some fragrances 
can be 25–50% DEP by volume (Agency for 
Toxic Substances and Disease Registry 1995). 
The inverse association with MEP and sensi-
tization among adults could suggest fragrance 
avoidance by allergen-sensitized individuals. 
Among Mexican-American adults, we saw a 
positive association with MEP. Other investi-
gators have noted that Mexican women who 
used multiple cosmetic and fragrance products 
had higher levels of MEP than those who did 
not, consistent with DEP exposure through 
the use of fragrances (Romero-Franco et al. 
2011). The differential findings for Mexican 
Americans warrant further characterization of 
their  exposures in the future.
Biological markers of phthalate metabo-
lites are often used to assess exposure because 
of the complexity of evaluating all sources of 
exposure. Although the use of biological mark-
ers is common, these phthalate measures are 
limited with respect to the time period they 
represent. The biological half-lives of these 
metabolites are < 1 day, and studies have 
shown that temporal variability in these mea-
sures limits their usefulness in estimating the 
associations with long-term exposure (Baird 
et al. 2010; Hauser et al. 2004; Hoppin et al. 
2002). Given the short biological half-lives of 
phthalates and the relatively nonvarying state 
of allergen-specific IgE in serum, our findings 
for allergic sensitization and HMW phthal-
ates should be considered cautiously. These 
findings might reflect a preference for plastics 
among those with allergic sensitization because 
these surfaces are easier to clean and less likely 
to be reservoirs for dusts and other allergic 
triggers. In contrast, our findings for allergic 
symptoms are less challenged by the use of 
biological markers because symptoms were 
experienced within the past year, although 
daily variation in exposure may influence these 
findings as well.
Our limited findings for children were 
unexpected given the previous literature. 
HMW phthalates, particularly DEHP, were 
associated with current rhinitis, but none of 
the associations were statistically significant. 
In a Swedish study, dust levels of BBzP were 
associated with rhinitis and eczema in chil-
dren 3–8 years of age, whereas dust levels of 
DEHP were associated with asthma; there 
was also some evidence of an association with 
rhinitis and DEHP in the highest quartile 
(Bornehag et al. 2004). Recently, Just et al. 
(2012b) reported that prenatal exposure to 
MBzP was associated with maternally reported 
eczema by 5 years of age and that current 
exposures were associated with higher frac-
tional exhaled nitric oxide (Just et al. 2012a). 
The HMW phthalate metabolites, MCOP 
and MCNP [mono(carboxynonyl) phthalate], 
were associated with current asthma in a cross-
sectional study of 623 Norwegian 10-year-
old children (Bertelsen et al. 2013); these two 
metabolites were not associated with respira-
tory symptoms in children or adults in our 
sample. In our analysis, there was no evidence 
of an association of any phthalates with cur-
rent itchy rash in either children or adults 
(data not shown). The lack of consistency with 
other studies may be related to the age of the 
children included in our analysis because no 
children < 6 years of age had data on urinary 
phthalates. Another possible explanation is 
that the relevant exposures for children are not 
those that are currently occurring but rather 
those that occurred earlier, such as prenatally. 
In addition, our study included a large rep-
resentative sample of children in the United 
States, whereas previous studies used smaller, 
more demographically similar groups. It may 
be that the diversity in our sample limited our 
ability to observe effects restricted to subsets of 
the population.
Phthalate metabolites, although chemi-
cally similar, are not highly correlated except 
for those derived from the same parent com-
pound. To minimize confounding by corre-
lated phthalates, we combined all metabolites 
from the same chemical (i.e., DEHP) into one 
summary variable. Given the multiple phthal-
ates and ways to consider allergy and allergic 
sensitization, we conducted many statistical 
analyses. Rather than correcting our results for 
the number of comparisons or limiting our 
presentation to those chemicals for which we 
had a priori evidence, we have chosen to pres-
ent our results uncorrected for multi ple com-
parisons and present the full results in order to 
provide a more complete picture of the com-
plexity of this research question.
Our previous work has shown poor con-
cordance between self-reported respiratory 
symptoms and allergic sensitization (Hoppin 
et al. 2011). To evaluate if our results for 
respiratory symptoms were driven by allergic 
sensitization, we ran additional models for 
those who were both allergen sensitized and 
had the allergic symptom. These results sug-
gested some interplay of allergic sensitization 
and symptoms in response to phthalates, but 
the evidence was inconclusive.
Conclusions
This study is the largest to date to evaluate 
associations between phthalates and allergic 
sensitization and symptoms in both adults 
and children. Although not entirely consis-
tent with previous studies, our study does 
provide additional evidence that phthalates, 
particularly HMW phthalates, may be associ-
ated with allergic symptoms in adults and 
possibly children. The findings were stronger 
in adults because HMW phthalates were gen-
erally positively associated with both allergic 
Table 6. ORs (95% CIs)a for MBzP and allergic symptoms, stratified by allergic sensitization in adults and 
children 6–17 years of age, NHANES 2005–2006.
Symptom/outcome
Adults Children
n OR (95% CI) pdifferenceb n OR (95% CI) pdifferenceb
Asthma 
No sensitization, no asthma 786 1.00 353 1.00
Current asthma only 40 0.71 (0.38, 1.31) 18 0.485 (0.16, 1.47)
Allergen sensitized only 635 1.27 (0.85, 1.90) 358 1.078 (0.68, 1.70)
Allergen sensitized and asthma 76 2.53 (1.43, 4.46) 0.011 47 1.55 (0.36, 6.67) 0.210
Hay fever
No sensitization, no hay fever 806 1.00 365 1.00
Hay fever only 19 2.28 (1.12, 4.64) 4 0.03 (0.004, 0.31)
Allergen sensitized only 647 1.37 (0.92, 2.06) 387 1.08 (0.70, 1.65)
Allergen sensitized and hay fever 69 1.87 (1.02, 3.44) 0.310 19 1.57 (0.29, 8.41) 0.011
Rhinitis
No sensitization, no rhinitis 591 1.00 310 1.00
Rhinitis only 235 1.21 (0.87, 1.69) 61 0.61 (0.31, 1.21)
Allergen sensitized only 455 1.40 (0.89, 2.21) 280 0.95 (0.59, 1.55)
Allergen sensitized and rhinitis 260 1.70 (1.07, 2.71) 0.481 126 1.38 (0.63, 3.04) 0.144
Wheeze
No sensitization, no wheeze 730 1.00 351 1.00
Wheeze only 96 1.34 (0.66, 2.73) 20 0.32 (0.10, 1.06)
Allergen sensitized only 594 1.25 (0.84, 1.85) 345 1.05 (0.65, 1.68)
Allergen sensitized and wheeze 123 2.74 (1.55, 4.83) < 0.001 60 1.57 (0.50, 4.98) 0.047
All models adjusted for age, race, gender, BMI, creatinine, and cotinine.
aORs for 1 log10 increase in MBzP concentration. bp-Value for difference of ORs using contrast statement in polytomous 
model.
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sensitization and symptoms in adults, but 
posi tively associated only with rhinitis in chil-
dren. The inverse association estimated for 
MEP and allergic sensitization is consistent 
with avoidance of compounds containing 
DEP by people who are allergen sensitized. 
We conducted this cross-sectional analysis of 
urinary phthalate levels and allergic sensitiza-
tion and symptoms in a large nationally rep-
resentative racially diverse sample, although 
generalizability to younger children is lim-
ited by the lack of phthalate data for children 
< 6 years of age. Future studies should not 
only better characterize the temporal associa-
tion between exposure and outcome, but they 
should also include measures such as allergen 
exposure in order to better understand the 
potential mecha nisms by which phthalates 
may  contribute to allergic outcomes.
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